PD. Dr. rer. physiol. Katja Bieber

1. Stussel P, Schulze Dieckhoff K, Kunzel S, Hartmann V, Gupta Y, Kaiser G, Visser R, Ghorbanalipoor S, Matsumoto K, Krause M, Petersen F, Kalies K, Ludwig RJ and Bieber K. Propranolol Is an Effective Topical and Systemic Treatment Option for Experimental Epidermolysis Bullosa Acquisita. J Invest Dermatol 2020;140:2408-20

2. Kasprick A, Hofrichter M, Smith B, Ward P, Bieber K, Shock A, Ludwig RJ, Schmidt E. Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. Br J Pharmacol 2020; 77:2381–2392

3. Vorobyev A, Gupta Y, Sezin T, Koga H, Bartsch Y, Belheouane M, Künzel S, Sina C, Schilf P, Körber-Ahrens H, Beltsiou F, Ernst A, Khilchenko S, Al-Aasam H, Manz R, Diehl S, Steinhaus M, Jascholt J, Kouki P, Boehncke W, Mayadas T, Zillikens D, Sadik C, Nishi H, Ehlers M, Möller S, Bieber K, Baines J, Ibrahim S, Ludwig RJ. Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line. Nat Commun 2019; 10:4097

4. Thieme M, Bieber K, Sezin T, Wannick M, Gupta Y, Kalies K, Ludwig RJ, Mousavi S, Zillikens D, Sadik CD. The Sphingosine-1-Phosphate Receptor Modulator Fingolimod Aggravates Murine Epidermolysis Bullosa Acquisita. J Invest Dermatol 2019; 139:2381-2384

5. Haeberle S, Wei X, Bieber K, Goletz S, Ludwig RJ, Schmidt E, Enk AH, Hadaschik EN. Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. J Allergy Clin Immunol 2018; 142:1831

6. Tukaj S*, Bieber K*, Witte M, Ghorbanalipoor S, Schmidt E, Zillikens D, Ludwig RJ, Kasperkiewicz M Calcitriol Treatment Ameliorates Inflammation and Blistering in Mouse Models of Epidermolysis Bullosa Acquisita. J Invest Dermatol 2018; 138:301

7. Bieber K*, Sun S*, Witte M, Kasprick A, Beltsiou F, Behnen M, Laskay T, Schulze FS, Pipi E, Reichhelm N, Pagel R, Zillikens D, Schmidt E, Sparwasser T, Kalies K, Ludwig RJ. Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases. Front Immunol 2017;8:1628

8. Bieber K, Ernst AL, Tukaj S, Holtsche MM, Schmidt E, Zillikens D, Ludwig RJ, Kasperkiewicz M. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. Exp Dermatol 2017; 26:1248

9. Hirose M, Kasprick A, Beltsiou F, Dieckhoff Schulze K, Schulze FS, Samavedam UK, Hundt JE, Pas HH, Jonkman MF, Schmidt E, Kalies K, Zillikens D, Ludwig RJ*, Bieber K*. Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment. Mol Med 2017; 22:918

10. Bieber K*, Witte M*, Sun S, Hundt JE, Kalies K, Dräger S, Kasprick A, Twelkmeyer T, Manz RA, König P, Köhl J, Zillikens D, Ludwig RJ. T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita. Sci Rep 2016; 6:38357